CYP2D6 is involved in the metabolism of several classes of drugs, including tricyclic antidepressants, selective serotonin reuptake inhibitors and various amphetamines. CYP2D6 Ã 10 is an allelic variant, producing an enzyme with Pro 34 Ser and Ser 486 Thr amino acid substitutions. Approximately 75% of Asians possess the Ã 10 allele. We sought to further characterize CYP2D6.10 catalytically in vitro in a baculovirus expression system using various substrates and inhibitors, in comparison to CYP2D6.1 (wild-type). Using dextromethorphan (DEX), P-methoxyamphetamine, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and (6)3,4-methylenedioxymethamphetamine (MDMA), the ratios of intrinsic clearance (V max /K m ) of Ã 1 to Ã 10 were 50, 34, 22 and 123, respectively. The CYP2D6 substrates amitriptyline, and ( ) and (2) methamphetamine (MAMP) are both p-hydroxylated and Ndemethylated (NDM). The intrinsic clearance Ã 1/ Ã 10 ratios were 42, 30 and 67 for the phydroxylation; and 60, 120 and 157 for the NDM, respectively, illustrating chemical pathway and enantiomeric selectivity for MAMP. It was apparent that ( ) and (2) MAMP NDM and MDMA demethylenation were most signi®cantly different in CYP2D6.10. Using DEX as the substrate, the ratios of K i ( Ã 10)/K i ( Ã 1) for inhibitors were: budipine (1.3), sparteine (1.6), debrisoquine (8.1),¯uoxetine (16), nor¯uoxetine (30), paroxetine (14), MDMA (21) and MMDA-2 (7.1), indicating that CYP2D6.10 shows drug-speci®c altered susceptibility to inhibition. Taken together, these data suggest that CYP2D6 Ã 10/ Ã 10 individuals may be expected to require different drug doses; and show altered susceptibility to toxicity, interaction risk and, in the case of the amphetamines, drug dependence and toxicity compared to CYP2D6 Ã 1/ Ã 1 individuals.
Introduction
Cytochrome P450s (CYPs) are the major Phase I biotransformation enzymes, responsible for maintaining homeostasis in metabolizing both endogenous substances and exogenous xenobiotics (Parkinson, 1996) . A major cause of interindividual and intergroup variation in drug effect is genetic variation of drug metabolism (Kalow, 1991) . CYP2D6 is a polymorphic enzyme, resulting in a bimodal distribution of extensive and poor metabolizers of CYP2D6 substrates in Caucasian populations (Maghoub et al., 1977; Eichelbaum et al., 1979; Bertilsson et al., 1992) . 5±10% of Caucasians are classi®ed as CYP2D6 poor metabolizers in contrast to only 1% of Asians (Alvan et al., 1990; Bertilsson et al., 1992) . Despite the very low prevalence of CYP2D6 poor metabolizers in Asians, this group displays lower mean CYP2D6 activity, as represented by a rightshift in the metabolic ratio for several CYP2D6 substrates, including debrisoquine, codeine and sparteine (Lou et al., 1987; Yue et al., 1989; Bertilsson et al., 1992; Yokota et al., 1993) . This lower overall CYP2D6 activity has been attributed to the high frequency of the CYP2D6.10 enzyme, possessing Pro 34 Ser and Ser 486 Thr amino acid mutations, present in approximately 75% of Asians (Wang et al., 1993; Johansson et al., 1994) . Recent clinical studies have demonstrated increased plasma concentrations and areas under concentration±time curves in CYP2D6 Ã 10/ Ã 1 and CYP2D6 Ã 10/ Ã 10 individuals versus CYP2D6 Ã 1/ Ã 1 individuals for a number of CYP2D6 substrates, including nortriptyline, venlafaxine, haloperidol, codeine and dextromethorphan (Yue et al., 1998; Caraco et al., 1999; Fukuda et al., 1999; Mihara et al., 1999; Tateishi et al., 1999; Yue et al., 1999) . In a previous in-vitro study characterizing CYP2D6.10, Johansson et al. demonstrated a signi®-cant reduction in protein levels and bufuralol 19-hydroxylation in COS-1 cells expressing both Pro 34 -Ser and Ser 486 Thr mutations (Johansson et al., 1994) . Detailed kinetic analyses, however, were not performed and only one substrate, bufuralol, was examined (Johansson et al., 1994) . A recent study by Fukuda et al. examined two substrates, venlafaxine and bufuralol, and found reduced af®nity of CYP2D6.10 for these compounds (Fukuda et al., 2000) . The focus of this investigation therefore was to examine the kinetic interactions of a panel of diverse CYP2D6 substrates and inhibitors with CYP2D6.10 in vitro. Differential metabolism and/or inhibition by these compounds in CYP2D6.10 will have implications on drug dosing, toxicity and the likelihood of drug±drug interactions in those with this variant enzyme. Ethnic variability in these kinetic effects may also be predicted, allowing for ethnic-speci®c pharmacotherapy.
Materials and methods

CHEMICALS
Dextromethorphan hydrobromide, dextrorphan tartrate, 3-hydroxymorphinan hydrochloride and 3-methoxymorphinan hydrobromide were provided by Hoffmann-LaRoche Inc. (Nutley, NJ, USA). Butorphanol tartrate, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), amitriptyline hydrochloride, nortriptyline hydrochloride, desipramine hydrochloride, sparteine, tryptamine, â-NADPH sodium salt and superoxide dismutase were purchased from Sigma Co. (St Louis, MO, USA). (AE)Nor¯uoxetine maleate and (AE)¯uoxetine were obtained from Eli Lilly Co. (Indianapolis, IN, USA). Debrisoquine sulfate was purchased from Research Biochemicals International (Natick, MA, USA). PTP was purchased from Toronto Research Chemicals (Ontario, Canada). (AE)3,4-Dihydroxymethamphetamine was kindly provided by Dr Arthur Cho. All other amphetamine analogues were provided by the National Institute on Drug Dependence, USA. High-performance liquid chromatography (HPLC)-grade methanol and acetonitrile were purchased from Fisher Scienti®c (Fair Lawn, NJ, USA). Ethyl acetate, ethyl ether, hexane and dichloromethane were all HPLC-grade and purchased from Caledon Laboratory Chemicals (Georgetown, ON, Canada). Potassium phosphate monobasic, heptane sulfonic acid, dibasic sodium carbonate and sodium bicarbonate were all ACS-grade.
CDNA-EXPRESSING MICROSOMES
cDNA-expressing microsomes were purchased from GenTest Co. (Woburn, MA, USA). CYP2D6.1 and CYP2D6.10 were each coexpressed with human cytochrome P450 oxidoreductase in BTI-TH-5B1-4 insect cells using a baculovirus expression vector. Both expression systems contain similar reductase to P450 ratios (0.9 : 1.0).
HPLC
A Hewlett-Packard 1100 isocratic pump, with a 1050 autosampler, 1050 UV detector and a HP339611 integrator were used for analyses. For MPTP analyses, a complete 100 HP 1100 series system with Chemstation was utilized.
SUBSTRATE ASSAYS
Incubations were carried out in 0.1 M KH 2 PO 4 buffer (pH 7.4) at 37 8C under continuous shaking. Preliminary studies were performed, using dextromethorphan (DEX) as the substrate, to determine incubation conditions under which dextrorphan (DOR) formation was linear with respect to time and CYP concentration. Incubation conditions were chosen for the substrates investigated following the establishment of linear conditions of product formation. Substrate, buffer and 1 mM NADPH were mixed in a ®nal volume of 200 ìl (except for MPTP where the ®nal volume was 500 ìl), and the reactions were initiated by the addition of enzyme. Total protein concentration was normalized in each assay, except p-methoxyamphetamine (PMA), by the addition of control insect cell microsomes provided by GenTest Co. For (AE)3,4-methylenedioxymethamphetamine (MDMA) studies, 30 U of superoxide dismutase were added to minimize conversion of dihydroxymethamphetamine to its O-quinone. Initial experiments to determine enzymatically formed peaks indicated a small production, of approximately 15%, of amphetamine from higher concentrations of methamphetamine (MAMP) (above 35.3 ìM), even when no enzyme was present, due to the apparent spontaneous chemical N-demethylation of MAMP. This background' amphetamine production was linear with the amount of MAMP incubated. In addition, similar amounts of amphetamine were produced in the absence of enzyme as in the presence of enzyme (without NADPH). Experiments were thus performed to measure this background amphetamine production, where all conditions and drug concentrations were identical, except that no enzyme was added. Enzymatically derived amphetamine for both CYP2D6.1 and CYP2D6.10 was then calculated by subtracting the amount of amphetamine formed in the presence of enzyme by the amount formed in the absence of enzyme. Substrate concentrations, enzyme amounts and incubation times used for each assay are summarized in Table 1 .
EXTRACTION
Dextromethorphan
Extraction procedure was essentially that of Chen et al. (1990) . After incubation, samples were placed on ice and 100 ìl of sodium bicarbonate buffer (pH 9.9) was added. The reaction was terminated by the addition of 1 ml of hexane : ether (4 : 1). Samples were vortexed and centrifuged for 10 min each, and back-extracted with 100 ìl of 0.01 N hydrochloric acid. Organic solvent was then aspirated, and 30 ìl of the remaining sample was injected into the HPLC [C 5 Waters Spherisorb column;¯ow rate 1 ml/min; UV 200 nm; 10 mM KH 2 PO 4 buffer containing 1 mM heptane sulphonic acid and acetonitrile (73:27, pH 3.8)]. For CYP2D6.10 studies, nor¯uox-etine was used as the internal standard; for CYP2D6.1 and all inhibition studies, butorphanol was used as the internal standard.
PMA
Extraction protocol was modi®ed from that of Li et al. (1997) . After incubation, samples were placed on ice and 300 ìl of sodium bicarbonate buffer (pH 9.9) was added. 3 ml of ethyl acetate was added in the presence of approximately 0.2 g NaCl crystals. Samples were shaken horizontally for 30 min, centrifuged for 10 min, and back-extracted with 200 ìl of 0.01 N HCl. Organic phase was aspirated, and 50 ìl was injected into the HPLC [C 6 Waters Spherisorb column;¯ow rate 1 ml/min; UV 214 nm; 10 mM KH 2 PO 4 buffer and acetonitrile (80:20, pH 6.0)]. 2-Methoxyamphetamine was used as the internal standard.
(AE) and (À) Methamphetamine Extraction and HPLC conditions were identical to those for PMA. 3-Methoxyamphetamine was used as the internal standard.
Amitriptyline
Extraction and HPLC conditions were identical to those for DEX. Desipramine was used as the internal standard.
MPTP
The reaction was terminated by the addition of 4 ml of dichloromethane. Samples were vortexed for 20 min and then centrifuged. The organic phase was then evaporated to dryness under nitrogen and the residue was redissolved in 200 ìl of mobile phase. Fifty ìl was then injected into the HPLC [CSC-Spherisorb-phenyl column;¯ow rate 1 ml/min; UV 244 nm; 100 mM KH 2 PO 4 buffer and acetonitrile (88 : 12; pH 3.0)]. Diethyltryptamine was used as the internal standard. DEX was incubated at ®nal concentrations of 0.5 K m , K m , and 2 K m for CYP2D6.1 and CYP2D6.10. Therefore, ®nal DEX concentrations used were 0.5 ìM, 1 ìM and 2 ìM for CYP2D6.1; and 2 ìM, 4 ìM, and 8 ìM for CYP2D6.10. Due to the high expense of the enzymes, 2-line K i s (at K m and 2 K m of DEX) were determined for budipine, MMDA-2 and MDMA. DOR production was monitored in the presence and absence of four different concentrations of each chemical inhibitor (50 ìl). Inhibitor concentrations were chosen based on initial screening experiments in which inhibitor concentrations of K i and 25 K i , based on previously published data, were incubated with 1 ìM of DEX. After the addition of inhibitor to DEX, 0.1 M sodium phosphate buffer and 50 ìl of NADPH (1 mM) were added. Incubation conditions are listed in Table 1. DATA ANALYSIS Kinetic parameters were calculated using Enz®tter computer software, version 1.05 (Elsevier Biosoft Inc., Amsterdam, The Netherlands) when the involvement of one enzyme was indicated. In the case of two-enzyme kinetics, Graphpad Prism software version 2.01 (Graphpad Software Inc., San Diego, CA, USA) was used. Dixon and Cornish±Bowden plots were generated using Microsoft Excel 97.
STATISTICAL ANALYSIS
A one-way ANOVA was used to determine the coef®-cient of variation based on replicates of K i , K m and V max values for eight substrate/inhibitor±enzyme combinations. The log ratios of K i in Ã 10 to K i in Ã 1 were sorted and compared using the Duncan New Multiple Range Test ( P , 0.05), allowing determination of signi®cant pairwise differences.
Results
Kinetics in CYP2D6.1 and CYP2D6.10 K m , V max and intrinsic clearance (V max /K m ) values, determined in CYP2D6.1-and CYP2D6.10-expressing microsomes, are summarized in Table 2 . Due to the high expense of these enzymes, replicate determinations were only conducted for selected substrates. As shown in Table 2 , large, substrate-dependent differences were observed between kinetic constants obtained with CYP2D6.10 compared to those obtained with CYP2D6.1. DEX, a selective CYP2D6 probe substrate which is O-demethylated to DOR, displayed average K m values of 0.8 and 5.0 ìM in CYP2D6.1 and CYP2D6.10 (Figs 1a,b), respectively; and an approximate 50-fold attenuated intrinsic clearance in CYP2D6.10.
PMA, a hallucinogenic central nervous system stimulant, is O-demethylated to its less active metabolite, p-hydroxyamphetamine. Similar to DEX, PMA demonstrated both reduced metabolism and af®nity with CYP2D6.10 versus CYP2D6.1. K m values of 37 and 78 ìM were determined in CYP2D6.1 and CYP2D6.10, respectively, and a 34-fold reduced invitro intrinsic clearance was observed with CYP2D6.10.
MAMP, a potent CNS stimulant, is both N-demethylated and p-hydroxylated to the less active metabolites, amphetamine and p-hydroxymethamphetamine, respectively (Cho & Kumagai, 1994) , and exists as both (+) and (À) enantiomers. With CYP2D6.1, N-demethylation of both (+) and (À)MAMP was more ef®ciently catalysed than the phydroxylation reaction, as demonstrated by the approximately three-fold higher intrinsic clearance values observed with N-demethylation (Table 2) . K m values of 12 and 285 ìM were obtained with (+)MAMP N-demethylation (Fig. 1c) ; while K m values of 28 and 300 ìM were determined with (À)MAMP N-demethylation, in CYP2D6.1 and CYP2D6.10, respectively. For p-hydroxylation, K m values of 23 and 97 ìM were obtained with (+)MAMP; while K m values of 52 and 385 ìM were obtained with (À)MAMP in CYP2D6.1 and CYP2D6.10, respectively. Therefore, with (+)MAMP, intrinsic clearance was reduced by 120-fold for the N-demethylation reaction in CYP2D6.10, but only 30-fold for the p-hydroxylation reaction. With (À)MAMP, a more pronounced attenuation was again seen with N-demethylation versus p-hydroxylation in CYP2D6.10, at 157-fold and 67-fold, respectively compared to CYP2D6.1. Amitriptyline (AMI), similar to MAMP, is both Ndemethylated and p-hydroxylated, to nortriptyline and E-10-hydroxyamitriptyline, respectively. How-ever, unlike MAMP, both the N-demethylation and p-hydroxylation of AMI were affected similarly in CYP2D6.10. K m values of 9.2 and 42 ìM were obtained for N-demethylation; while K m values of 1.8 and 5.8 ìM were obtained for p-hydroxylation in CYP2D6.1 and CYP2D6.10, respectively. Intrinsic clearances were reduced by 60-and 42-fold for AMI N-demethylation and p-hydroxylation in CYP 2D6.10, respectively compared to CYP2D6.1.
MPTP is a neurotoxin which is N-demethylated to 4-phenyl-1,2,3,6-tetrahydropyridine (PTP). MPTP metabolism in CYP2D6.10 was the least different from CYP2D6.1, although intrinsic clearance was still reduced by an approximately 20-fold in CYP2D6.10. K m values of 43 and 103 ìM were determined in CYP2D6.1 and CYP2D6.10, respectively.
In contrast to MPTP, MDMA demethylenation (to 3,4-dihydroxymethamphetamine) in CYP2D6.10 was among the compounds most different from CYP2D6.1. K m values of 1.3 and 21 ìM were determined in CYP2D6.1 and CYP2D6.10, respectively, for MDMA demethylenation. Accordingly, intrinsic clearance values were substantially reduced in CYP2D6.10, demonstrating approximately 120-fold less activity than CYP2D6.1.
Differences between substrates
The decreases in intrinsic clearance seen with all of the substrates investigated were a result of both decreases in substrate af®nity (K m ) and reaction velocity (V max ). These effects, however, were not uniform across the substrates. To assess variation between substrates and chemical pathways, we determined statistically signi®cant differences in the ratios of K m and intrinsic clearance values obtained in CYP2D6.10, compared to those obtained in CYP2D6.1. The af®nities of (+) and (À)MAMP Ndemethylation (NDM) and MDMA demethylenation for CYP2D6.10 were the most attenuated, relative to CYP2D6.1, demonstrating 24-fold, 11-fold and 16-fold higher K m values, respectively. Conversely, the af®nities of p-methoxyamphetamine and MPTP for CYP2D6.10 were the most similar to CYP2D6.1, both displaying only approximately two-fold increases in K m in CYP2D6.10. Chemical pathway selectivity was also evident, with the K m for (+)MAMP NDM being signi®cantly more affected in CYP2D6.10 than (+)MAMP p-hydroxylation. With intrinsic clearance (+) and (À)MAMP Ndemethylation (NDM), MDMA demethylenation and MPTP NDM displayed signi®cantly different ratios from the greatest number of other substrates, with (À)MAMP NDM (+)MAMP NDM and MDMA being signi®cantly smaller than several other substrates. Conversely, the log intrinsic clearance ratio ( Ã 10/ Ã 1) for MPTP (+)MAMP p-hydroxylation and PMA were signi®cantly higher than those for several other substrates.
There were also signi®cant differences between intrinsic clearance ratios ( Ã 10/ Ã 1) between the enantiomers of MAMP, with the ratio for (À)MAMP phydroxylation being signi®cantly lower than that for (+)MAMP. Differences between the metabolic pathways of (+) and (À)MAMP were also noted, with the NDM of both (+) and (À)MAMP being signi®cantly lower than for the p-hydroxylation pathway, with the effects being more predominant with (+)MAMP. No signi®cant differences were seen amitriptyline NDM and its p-hydroxylation.
Inhibition of CYP2D6.1 and CYP2D6.10
In addition to substrates, the interactions of a number of inhibitors of varying drug classes with CYP2D6.1 and CYP2D6.10 were studied. DEX was chosen as the probe CYP2D6 substrate because of its high selectivity and speci®city for CYP2D6. The inhibitors were chosen in an effort to select compounds from different drug classes to allow for assessment of potential differences between drug classes and chemical structures. Nor¯uoxetine,¯uox-etine and paroxetine are all selective serotonin reuptake inhibitors (SSRIs). MMDA-2 and MDMA are both methylenedioxy-substituted amphetamines. Sparteine and debrisoquine are not from the same drug class but, along with dextromethorphan, are commonly used CYP2D6 probe substrates used for phenotyping. Therefore, inhibition studies with these compounds revealed potential differences in their metabolism by CYP2D6.10. Finally, budipine is a highly selective probe CYP2D6 inhibitor, which was used as a positive control for CYP2D6 inhibition. Average K i values, with individual determinations in parentheses, for all the compounds examined are listed in Table 3 . All compounds demonstrated competitive inhibition of CYP2D6.1 and CYP2D6.10, except paroxetine, which displayed mixed inhibition in CYP2D6.1. All inhibitors displayed greater K i values in CYP2D6.10 than in CYP2D6.1, though to varying degrees. The ratios of K i values obtained in CYP2D6.10 compared to those in CYP2D6.1 varied from 1.3 and 1.6 for budipine and sparteine, respectively, showing little difference between the two alleles, to 20-and 30-fold for MDMA and nor¯uox-etine, respectively, demonstrating signi®cant differences between CYP2D6.1 and CYP2D6.10. This 20-fold difference in K i values for MDMA was very similar to the 16-fold difference obtained with K m , providing validation of the signi®cant attenuation of MDMA af®nity for CYP2D6.10. It was also demonstrated that debrisoquine displayed a signi®cantly greater K i ratio ( Ã 10/ Ã 1) (8.3) than did sparteine (1.6), illustrating differential interactions of the two compounds with CYP2D6.10. Dixon and Cornish± Bowden plots for sparteine in CYP2D6.1 and CYP2D6.10, indicating competitive inhibition, are illustrated in Fig. 2 .
Discussion
With all the substrates examined, CYP2D6.10 exhibited decreased metabolism and reduced af®nity, as compared to CYP2D6.1 (Table 2 ). These effects manifested as reductions in in-vitro intrinsic clearances of all the substrates. The reduced substrate af®nity observed here is in line with a recent study demonstrating an approximate ®ve-fold reduction in K m values for bufuralol and venlafaxine in cDNAexpressed CYP2D6.10 versus CYP2D6.1 (Fukuda et al., 2000) . In the present study, several different substrates were examined enabling some distinctions between substrates to be made. It was found that the K m ratios ( Ã 10/ Ã 1) for (+)MAMP NDM and MDMA demethylenation were signi®cantly lower than seven and ®ve other substrates, respectively. In contrast to MAMP and MDMA, PMA and MPTP were among the least different in both drug af®nity and intrinsic clearance in CYP2D6.10 versus CYP2D6.1. Differential effects on af®nity for different CYP2D6 substrates have been previously observed with CYP2D6.17, where K m s for codeine and bufuralol were approximately ®ve-fold versus 10-fold greater, respectively, compared to CYP2D6.1 (Oscarson et al., 1997) . CYP2D6.10 has single amino acid mutations including one that is also present in CYP2D6.17 (Ser 486 Thr) and has been implicated in enzyme± substrate interactions (Gotoh, 1992) , which may underlie the differences in substrate af®nity that were observed. The particularly profound effects with MAMP and MDMA in CYP2D6.10 suggest that certain key chemical components on these molecules Table 3 . Summary of inhibition of dextromethorphan metabolism in CYP2D6.1-and CYP2D6.10-expressing microsomes may be especially important in constraining their interactions with CYP2D6.10, such as through increased steric hindrance. MAMP and MDMA, both being amphetamines, are similar structurally. It is not clear why the K m of p-methoxyamphetamine, which is also related chemically to MAMP and MDMA, was not as signi®cantly affected in CYP2D6.10. The presence of the methoxy group on PMA may act to increase its af®nity for CYP2D6.10. MPTP was also less affected in its af®nity for CYP2D6.10 in comparison to other substrates. Both compounds bear no obvious structural similarities, making further conclusions dif®cult. Since only a few substrates were studied, it is dif®cult to extrapolate the results to chemical structure determinants. Continued screening of different substrates and inhibitors is necessary to better evaluate characteristics of compounds which display signi®cantly different catalytic activity in CYP2D6.10 compared to CYP2D6.1. In addition to substrate-selectivity, enantiomeric differences in metabolism were observed with CYP2D6.10. MAMP exists in (+) and (À) enantiomers, with the (+) enantiomer being a more potent CNS stimulant (Cho, 1990) . In CYP2D6.10 (À)MAMP p-hydroxylation was signi®cantly more attenuated compared to CYP2D6.1 than (+)MAMP p-hydroxylation.
Enantiomeric differences in methamphetamine metabolism have been previously demonstrated with CYP2D6.1, in that (À)MAMP has been shown to have a lower in-vitro intrinsic clearance than the (+) enantiomer for both NDM and phydroxylation (Lin et al., 1997) . The present results suggest such differences may also occur with CYP2D6.10. In vivo, one may expect CYP2D6 Ã 10/ Ã 10 individuals to have higher plasma levels of the less potent (À)MAMP, compared to (+)MAMP, after ingesting (AE)MAMP.
A common characteristic of substrates of CYP2D6 is that they possess one or more basic nitrogen atoms, with the site of oxidation of most CYP2D6 substrates residing 5±7 A Ê from the basic nitrogen (Koymans et al., 1992) . This structural requirement makes N-demethylation at the basic nitrogen an unlikely chemical reaction catalysed by CYP2D6, although exceptions have been observed, including amitriptyline and MPTP (Coutts et al., 1994; Grace et al., 1994; Coleman et al., 1996; Rowland et al., 1996; Ghahramani et al., 1997; Olesen & Linnet, 1997 ). An alternative model involving differential positioning of the active site and electron transfer from the free base, has been proposed to account for these exceptions (Grace et al., 1994) . It was surprising, however, that amitriptyline, MPTP and MAMP which are N-demethylated at sites less than 5±7 A Ê from the basic nitrogen, were all signi®cantly catalysed by CYP2D6.1. In fact, in CYP2D6.1-expressing microsomes, N-demethylation of (+) and (À)MAMP was more signi®cant than the predicted p-hydroxy- lation pathway. MAMP N-demethylation has been previously observed in yeast-expressing CYP2D6, at a higher rate than the corresponding p-hydroxylation reaction (Lin et al., 1997) . Moreover, a correlation between MAMP N-demethylation and metoprolol hydroxylation has been observed in a panel of human livers (Lin et al., 1997) . The high MAMP Ndemethylation activity seen in expressed CYP2D6.1 is likely due to the high activity of the expression system. In addition, it may be that the slow hydroxylation of the aromatic ring of MAMP may allow the substrate to reposition in the catalytic site, making N-demethylation more likely. This so-called`metabolic switching' has been previously proposed by others (Lin et al., 1997) .
In-vitro studies of CYP2D6 have demonstrated that the Pro 34 Ser amino acid substitution results in reduced enzyme expression in COS and yeast cells (Johansson et al., 1994; Fukuda et al., 2000) , suggesting that, in vivo, CYP2D6.10 may be present in lower amounts that CYP2D6.1. These studies, combined with the reduced af®nity and ef®ciency observed here with CYP2D6.10, indicate that individuals with CYP2D6 Ã 10 would display decreased metabolism of these compounds in vivo. The substantial in-vitro differences between CYP2D6.1 and CYP2D6.10 suggest that reduced metabolism would be observed in both homozygotes and heterozygotes of CYP2D6 Ã 10. Consequently, increased concentrations of parent drug would result, which may translate into an increased risk of side-effects. These effects would be more likely if CYP2D6 plays a large role in the clearance of the substrate; and if the substrate has a narrow therapeutic index. CYP2D6 has been demonstrated to be the major enzyme involved in the metabolism of DEX, PMA and MDMA, and the p-hydroxylation of AMI (Kitchen et al., 1979; Tucker et al., 1994; Wu et al., 1997; Nordin & Bertilsson, 1998; von Moltke et al., 1998; Kreth et al., 2000) . Therefore, it is likely that those with CYP2D6 Ã 10 will have signi®cantly elevated plasma levels of these compounds. Indeed, Tateishi and coworkers demonstrated an approximate 50-fold decrease in DEX log MRs in CYP2D6 Ã 10/ Ã 10 individuals relative to CYP2D6 Ã 1/ Ã 1 individuals (Tateishi et al., 1999) . Given the likely importance of PMA Odemethylation in vivo (Kitchen et al., 1979) , the observed 35-fold reduced in-vitro PMA metabolism may result in a substantial decrease in PMA metabolism in CYP2D6 Ã 10/ Ã 10 individuals. Since PMA is more centrally active than its metabolite, p-hydroxyamphetamine (Burde & Thompson, 1991) , decreased metabolism of PMA by CYP2D6.10 indicates that CYP2D6 Ã 10/ Ã 10 individuals may experience greater central stimulant effects at equal doses as those used by CYP2D6 Ã 1/ Ã 1 individuals. Moreover, increased plasma PMA levels may result in enhanced systemic toxicity, because it produces marked and sustained elevations in blood pressure and hyperthermia in some users (Sellers et al., 1979) .
MDMA displayed a signi®cant attenuation in intrinsic clearance in CYP2D6.10 (Table 2) , to less than 1/120 the activity of CYP2D6.1. Therefore, one would expect signi®cantly elevated plasma concentrations of MDMA in those with CYP2D6 Ã 10, relative to CYP2D6 Ã 1/ Ã 1 individuals. Several deaths have been attributed to MDMA use, which appear to occur even in those taking average doses (Henry et al., 1992) . Reduced metabolism of MDMA, such as through CYP2D6.10, may result in toxic levels of MDMA, leading to cardiovascular and hyperthermic complications. In-vivo studies with MDMA in those of varied CYP2D6 genotype are required to understand the effect of polymorphism on the pharmacokinetics and pharmacodynamics of MDMA.
Similar to MDMA (+) and (À)MAMP N-demethylation were signi®cantly decreased in CYP2D6.10-expressing microsomes, as was p-hydroxylation, although to a lesser extent. The low intrinsic clearance observed presently in CYP2D6.1-expressing microsomes (Table 2) suggests that CYP2D6 may not be important in the overall clearance of MAMP. Data from pooled human liver microsomes indicated a similar low intrinsic clearance (data not shown), again suggesting a lack of importance of CYP450-catalysed reactions in overall MAMP clearance. The role of CYP2D6 polymorphism in MAMP metabolism and drug effect therefore remains to be established.
Given the reported minor role of p-hydroxylation in the clearance of AMI (Nordin & Bertilsson, 1998) , and the inconclusive evidence of the role of CYP2D6 in its N-demethylation, the effects of CYP2D6 polymorphism on the pharmacokinetics of AMI are less clear. Similarly, the role of competing pathways in MPTP metabolism (Chiba et al., 1988) may decrease the importance of the CYP2D6-catalysed N-demethylation reaction, though it has been shown that the rat model for the CYP2D6 poor metabolzers phenotype displayed a more pronounced and maintained de®cit in motor activity after treatment with MPTP than the extensive metabolizer rat model (JimenezJimenez et al., 1991) . Further characterization of the enzyme(s) involved in these reactions is necessary.
The SSRIs and amphetamines studied all displayed signi®cantly different inhibition of CYP2D6.10, as compared to CYP2D6.1. Thus, one may expect that in vivo, CYP2D6 Ã 10/ Ã 10 individuals would display decreased susceptibility to inhibition by these drugs. In contrast to the SSRIs and amphetamine analogues, budipine and sparteine inhibition constants were minimally affected with CYP2D6.10 in vitro. These results suggest that these compounds are not especially constrained from interacting with the CYP2D6.10 active site. Since similar K i s were determined in CYP2D6.10 and CYP2D6.1 for these compounds, one may expect to observe similar inhibition pro®les with these compounds in vivo in CY-P2D6 Ã 10/ Ã 10 and CYP2D6 Ã 1/ Ã 1 individuals. One must bear in mind, however, that the degree of invivo inhibition also depends on factors other than K i , including inhibitor concentration at the enzyme site and enzyme saturability. In addition, the signi®cantly different effects observed with sparteine and debrisoquine in CYP2D6.10 suggest that the two may interact differentially as substrates with this enzyme, though further studies are necessary.
In conclusion, the present study indicates that CYP2D6.10 is an enzyme of both reduced af®nity and ef®ciency compared to CYP2D6.1. Moreover, CYP2D6.10 displays substrate-, chemical pathwayand enantiomeric-selectivity with the compounds studied, indicating that extrapolating to metabolism of other substrates in individuals with this allele, relative to CYP2D6.1, may not be possible. Finally, these profound and variable reductions in CYP2D6.10-catalysed metabolism suggest that CYP2D6.10 should be taken into account during the drug development process.
